Devinder Singh Rana

Devinder Singh Rana

Auto-generated profile, based on publicly available information

Devinder Singh Rana

Department of Nephrology, Sir Ganga Ram Hospital, New Delhi, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2012 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MRMohan M Rajapurkar
Mohan M Rajapurkar
GJGeorge T John
George T John
AKAshok L Kirpalani
Ashok L Kirpalani
GAGeorgi Abraham
Georgi Abraham
SASanjay K Agarwal
Sanjay K Agarwal
VJVivekanand Jha
Vivekanand Jha
Background: There are no national data on the magnitude and pattern of chronic kidney disease (CKD) in India. The Indian CKD Registry documents the demographics, etiological spectrum, practice patterns, variations and special characteristics. Methods: Data was collected for this cross-sectional study in a standardized format according to predetermined criteria. Of the 52,273 adult patients, 35.5%, 27.9%, 25.6% and 11% patients came from South, North, West and East zones respectively. Results: The mean age was 50.1 ± 14.6 years, with M:F ratio of 70:30. Patients from North Zone were younger and those from the East Zone older. Diabetic nephropathy was the commonest cause (31%), followed by CKD of undetermined etiology (16%), chronic glomerulonephritis (14%) and hypertensive nephrosclerosis (13%). About 48% cases presented in Stage V; they were younger than those in Stages III-IV. Diabetic nephropathy patients were older, more likely to present in earlier stages of CKD and had a higher frequency of males; whereas those with CKD of unexplained etiology were younger, had more females and more frequently presented in Stage V. Patients in lower income groups had more advanced CKD at presentation. Patients presenting to public sector hospitals were poorer, younger, and more frequently had CKD of unknown etiology. Conclusions: This report confirms the emergence of diabetic nephropathy as the pre-eminent cause in India. Patients with CKD of unknown etiology are younger, poorer and more likely to present with advanced CKD. There were some geographic variations.

28 May 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
ASAjay K Singh
Ajay K Singh
YFYoussef Mk Farag
Youssef Mk Farag
BMBharati V Mittal
Bharati V Mittal
KSKuyilan Karai Subramanian
Kuyilan Karai Subramanian
SRSai Ram Keithi Reddy
Sai Ram Keithi Reddy
MRMohan M Rajapurkar
Mohan M Rajapurkar
There is a rising incidence of chronic kidney disease that is likely to pose major problems for both healthcare and the economy in future years. In India, it has been recently estimated that the age-adjusted incidence rate of ESRD to be 229 per million population (pmp), and >100,000 new patients enter renal replacement programs annually. We cross-sectionally screened 6120 Indian subjects from 13 academic and private medical centers all over India. We obtained personal and medical history data through a specifically designed questionnaire. Blood and urine samples were collected. The total cohort included in this analysis is 5588 subjects. The mean ± SD age of all participants was 45.22 ± 15.2 years (range 18–98 years) and 55.1% of them were males and 44.9% were females. The overall prevalence of CKD in the SEEK-India cohort was 17.2% with a mean eGFR of 84.27 ± 76.46 versus 116.94 ± 44.65 mL/min/1.73 m2 in non-CKD group while 79.5% in the CKD group had proteinuria. Prevalence of CKD stages 1, 2, 3, 4 and 5 was 7%, 4.3%, 4.3%, 0.8% and 0.8%, respectively. The prevalence of CKD was observed to be 17.2% with ~6% have CKD stage 3 or worse. CKD risk factors were similar to those reported in earlier studies. It should be stressed to all primary care physicians taking care of hypertensive and diabetic patients to screen for early kidney damage. Early intervention may retard the progression of kidney disease. Planning for the preventive health policies and allocation of more resources for the treatment of CKD/ESRD patients are imperative in India.

30 June 2021 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
SVSagar Verma
Sagar Verma
PSPriyanka Singh
Priyanka Singh
SKShiffali Khurana
Shiffali Khurana
NGNirmal Kumar Ganguly
Nirmal Kumar Ganguly
RKRitushree Kukreti
Ritushree Kukreti
VBVinant Bhargava
Vinant Bhargava
Moderate levels of endogenous reactive oxygen species (ROS) are important for various cellular activities, but high levels lead to toxicity and are associated with various diseases. Levels of ROS are maintained as a balance between oxidants and antioxidants. Accumulating data suggest that oxidative stress is a major factor in deterioration of renal function. In this review, we highlight the possible mechanism by which oxidative stress can lead to chronic kidney disease (CKD). This review also describes therapies that counter the effect of oxidative stress in CKD patients. Numerous factors such as upregulation of genes involved in oxidative phosphorylation and ROS generation, chronic inflammation, vitamin D deficiency, and a compromised antioxidant defense mechanism system cause progressive detrimental effects on renal function that eventually lead to loss of kidney function. Patients with renal dysfunction are highly susceptible to oxidative stress, as risk factors such as diabetes, renal hypertension, dietary restrictions, hemodialysis, and old age predispose them to increased levels of ROS. Biomolecular adducts (DNA, proteins, and lipids) formed due to reaction with ROS can be used to determine oxidative stress levels. Based on the strong correlation between oxidative stress and CKD, reversal of oxidative stress is being explored as a major therapeutic option. Xanthine oxidase inhibitors, dietary antioxidants, and other agents that scavenge free radicals are gaining interest as treatment modalities in CKD patients.

27 July 2021 in Nephrology
Verified
Journal Article
Closed access
PDF file
VBVinant Bhargava
Vinant Bhargava
SJSanjiv Jasuja
Sanjiv Jasuja
STSydney Chi‐Wai Tang
Sydney Chi‐Wai Tang
ABAnil BHALLA
Anil BHALLA
GSGaurav Sagar
Gaurav Sagar
MGMaurizio Gallieni
Maurizio Gallieni

6 May 2021 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
SASuceena Alexander
Suceena Alexander
SJSanjiv Jasuja
Sanjiv Jasuja
MGMaurizio Gallieni
Maurizio Gallieni
MSManisha Sahay
Manisha Sahay
DRDevender S. Rana
Devender S. Rana
TVTushar Vachharajani
Tushar Vachharajani
Background. The association between economic status and kidney disease is incompletely explored even in countries with higher economy (HE); the situation is complex in lower economies (LE) of South Asia and Southeast Asia (SA and SEA). Methods. Fifteen countries of SA and SEA categorized as HE and LE, represented by the representatives of the national nephrology societies, participated in this questionnaire and interview-based assessment of the impact of economic status on renal care. Results. Average incidence and prevalence of end-stage kidney disease (ESKD) per million population (pmp) are 1.8 times and 3.3 times higher in HE. Hemodialysis is the main renal replacement therapy (RRT) (HE-68, LE-63). Funding of dialysis in HE is mainly by state (65) or insurance bodies (30); out of pocket expenses (OOPE) are high in LE (41). Highest cost for hemodialysis is in Brunei and Singapore, and lowest in Myanmar and Nepal. Median number of dialysis machines/1000 ESKD population is 110 in HE and 53 in LE. Average number of machines/dialysis units in HE is 2.7 times higher than LE. The HE countries have 9 times more dialysis centers pmp (median HE-17, LE-02) and 16 times more nephrologist density (median HE-14.8ppm, LE-0.94ppm). Dialysis sessions >2/week is frequently followed in HE (84) and <2/week in LE (64). On-demand hemodialysis (10 in all the HE countries except Taiwan, 1020 in the majority of LE countries. Conclusion. Economic disparity in SA and SEA is reflected by poor dialysis infrastructure and penetration, inadequate manpower, higher OOPE, higher dialysis dropout rates, and lesser renal transplantations in LE countries. Utility of RRT can be improved by state funding and better insurance coverage.

10 November 2020 in Nephrology
Verified
Journal Article
Closed access
PDF file
MSManisha Sahay
Manisha Sahay
SJSanjiv Jasuja
Sanjiv Jasuja
STSydney Chi Wai Tang
Sydney Chi Wai Tang
SASuceena Alexander
Suceena Alexander
VJVivekanand Jha
Vivekanand Jha
MGMaurizio Gallieni
Maurizio Gallieni